Bio markers- the new diagnostic tool.
Blood test that can detect dementia with 90% accuracy could lead to Alzheimer’s cure | National Post
A blood test for Alzheimer’s capable of predicting whether a person will develop dementia has been developed in a breakthrough hailed by campaigners.
The test could ultimately lead to successful treatment that would halt or even prevent the disease, scientists said.
The research found that biomarkers in the blood could be used to forecast whether a person would develop Alzheimer’s disease within three years with a 90% level of accuracy.
Charities said Sunday that the findings from the American trial were encouraging and could signify an important advance in dementia treatment.
However, they also warned of ethical dilemmas ahead and said patients must be given a choice about whether they wanted to receive potentially devastating news about their future.
Jeremy Hunt, Britain’s health secretary, told an international summit on dementia last month that the development of such tests could constitute “a massive step forward” in the battle against the disease.
Dr Doug Brown, director of research and development at the Alzheimer’s Society, said: “This is a really welcome development — it takes us a step closer to something that could impact on the lives of thousands of people with dementia.”
The research, published in the journal Nature Medicine, identified 10 molecules in the blood that could be used to predict with at least 90% accuracy whether people went on to develop mild cognitive impairment or Alzheimer’s. It is the first study to show differences in biomarkers in the blood between those who went on to suffer the disease, and those who remained “cognitively normal”.
Researchers from Georgetown University Medical Centre in Washington DC said blood tests to identify those likely to develop dementia could be used in major clinical trials within two years.
Existing drugs for Alzheimer’s disease work best if given early, and can lessen the symptoms, but do not slow overall progression of disease.
Related
Alzheimer’s risk much higher in those exposed to banned pesticide: study | National Post
The DIY dementia test: sample questions from the quiz doctors claim will catch Alzheimer’s early | National Post
Scientists believe the best hope of finding a breakthrough treatment, which can slow or reverse progression of the condition, may come if drugs can be given long before patients show signs of disease.
Professor Howard Federoff, one of the study’s authors, said that being able to predict the disease before it was symptomatic could offer a “window of opportunity” that could be critical to developing effective drugs to combat the condition before it took hold.
Researchers said the results were “a major step forward” towards introducing large-scale screening to identify at-risk individuals, and test possible treatments and preventative drugs.
Dr Simon Ridley, the head of research at the charity Alzheimer’s Research UK, said: “Alzheimer’s disease begins to develop long before symptoms such as memory loss appear, but detecting the disease at this pre-symptomatic stage has so far proved difficult.
“More work is needed to confirm these findings, but a blood test to identify people at risk of Alzheimer’s could be an important finding for research.”
He said further studies were needed on larger groups of people, to see if treatments were more effective if given earlier. “These are encouraging findings, but it’s vital to continue investing in research to capitalise on results like these,” he said.
The results are ‘a major step forward’ towards introducing large-scale screening to identify at-risk individuals
Scientists from Georgetown University Medical Centre examined 525 healthy participants aged 70 and over and monitored them for five years.
They regularly analysed blood samples from 53 participants who developed dementia, comparing them with those from 53 “cognitively normal” people.
When they tracked back, they found that the biomarkers could predict with 90 per cent accuracy whether participants went on to develop Alzheimer’s disease or mild cognitive impairment.
Prof Federoff, a professor of neurology at Georgetown University, said: “The lipid panel was able to distinguish with 90% accuracy these two distinct groups: cognitively normal participants who would progress to mild cognitive impairment or Alzheimer’s disease within two to three years, and those who would remain normal in the near future.”
The researchers are now designing a further study in which those forecast to have a high risk of Alzheimer’s are given access to experimental treatments that may delay or prevent the condition.
One in three people will develop dementia in their lifetime, and a rapidly ageing population means that the numbers are forecast to double within two decades.
More than 800,000 people in the U.K. have a form of dementia — most commonly Alzheimer’s disease — but government estimates suggest that just half of cases receive a diagnosis.
Blood test that can detect dementia with 90% accuracy could lead to Alzheimer’s cure | National Post
A blood test for Alzheimer’s capable of predicting whether a person will develop dementia has been developed in a breakthrough hailed by campaigners.
The test could ultimately lead to successful treatment that would halt or even prevent the disease, scientists said.
The research found that biomarkers in the blood could be used to forecast whether a person would develop Alzheimer’s disease within three years with a 90% level of accuracy.
Charities said Sunday that the findings from the American trial were encouraging and could signify an important advance in dementia treatment.
However, they also warned of ethical dilemmas ahead and said patients must be given a choice about whether they wanted to receive potentially devastating news about their future.
Jeremy Hunt, Britain’s health secretary, told an international summit on dementia last month that the development of such tests could constitute “a massive step forward” in the battle against the disease.
Dr Doug Brown, director of research and development at the Alzheimer’s Society, said: “This is a really welcome development — it takes us a step closer to something that could impact on the lives of thousands of people with dementia.”
The research, published in the journal Nature Medicine, identified 10 molecules in the blood that could be used to predict with at least 90% accuracy whether people went on to develop mild cognitive impairment or Alzheimer’s. It is the first study to show differences in biomarkers in the blood between those who went on to suffer the disease, and those who remained “cognitively normal”.
Researchers from Georgetown University Medical Centre in Washington DC said blood tests to identify those likely to develop dementia could be used in major clinical trials within two years.
Existing drugs for Alzheimer’s disease work best if given early, and can lessen the symptoms, but do not slow overall progression of disease.
Related
Alzheimer’s risk much higher in those exposed to banned pesticide: study | National Post
The DIY dementia test: sample questions from the quiz doctors claim will catch Alzheimer’s early | National Post
Scientists believe the best hope of finding a breakthrough treatment, which can slow or reverse progression of the condition, may come if drugs can be given long before patients show signs of disease.
Professor Howard Federoff, one of the study’s authors, said that being able to predict the disease before it was symptomatic could offer a “window of opportunity” that could be critical to developing effective drugs to combat the condition before it took hold.
Researchers said the results were “a major step forward” towards introducing large-scale screening to identify at-risk individuals, and test possible treatments and preventative drugs.
Dr Simon Ridley, the head of research at the charity Alzheimer’s Research UK, said: “Alzheimer’s disease begins to develop long before symptoms such as memory loss appear, but detecting the disease at this pre-symptomatic stage has so far proved difficult.
“More work is needed to confirm these findings, but a blood test to identify people at risk of Alzheimer’s could be an important finding for research.”
He said further studies were needed on larger groups of people, to see if treatments were more effective if given earlier. “These are encouraging findings, but it’s vital to continue investing in research to capitalise on results like these,” he said.
The results are ‘a major step forward’ towards introducing large-scale screening to identify at-risk individuals
Scientists from Georgetown University Medical Centre examined 525 healthy participants aged 70 and over and monitored them for five years.
They regularly analysed blood samples from 53 participants who developed dementia, comparing them with those from 53 “cognitively normal” people.
When they tracked back, they found that the biomarkers could predict with 90 per cent accuracy whether participants went on to develop Alzheimer’s disease or mild cognitive impairment.
Prof Federoff, a professor of neurology at Georgetown University, said: “The lipid panel was able to distinguish with 90% accuracy these two distinct groups: cognitively normal participants who would progress to mild cognitive impairment or Alzheimer’s disease within two to three years, and those who would remain normal in the near future.”
The researchers are now designing a further study in which those forecast to have a high risk of Alzheimer’s are given access to experimental treatments that may delay or prevent the condition.
One in three people will develop dementia in their lifetime, and a rapidly ageing population means that the numbers are forecast to double within two decades.
More than 800,000 people in the U.K. have a form of dementia — most commonly Alzheimer’s disease — but government estimates suggest that just half of cases receive a diagnosis.
